Sharon Tollin on Research Into Risk-Reducing Surgery

Neoadjuvant pembrolizumab elicited high clinical activity in patients with mismatch repair deficiency/microsatellite instability high solid tumors and was well tolerated.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.

January is cervical cancer awareness month. This third article in a series highlights current cervical cancer treatment options.